Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy has demonstrated significant success in treating hematological malignancies.
• Epithelial malignancies, which constitute the majority of cancer cases, present unique challenges due to their evasion of immune attack.

Purpose of the Study:

• To review the principles of CAR T cell design.
• To discuss the application of CAR T cell therapy to solid tumors.
• To explore potential solutions for overcoming obstacles in solid tumor treatment.

Main Methods:

• Review of scientific literature on CAR T cell therapy principles and clinical results.
• Analysis of challenges in applying CAR T cell therapy to solid tumors.
• Discussion of advances in genetic engineering, synthetic biology, and T cell biology.

Main Results:

• CAR T cell therapy targeting CD19 has shown extraordinary efficacy in B cell malignancies.
• Significant obstacles hinder the application of CAR T cell therapy to solid tumors.
• Advances in related fields offer potential solutions for solid tumor treatment.

Conclusions:

• CAR T cell therapy is highly effective for certain blood cancers.
• Translating CAR T cell therapy success to solid tumors requires overcoming substantial hurdles.
• Interdisciplinary advancements are crucial for future CAR T cell therapy development in solid tumors.